Last reviewed · How we verify
Philogen S.p.A. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
9 Phase 2
9 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Daromun | Daromun | phase 3 | Other | |||
| L19IL2 + L19TNF | L19IL2 + L19TNF | phase 3 | Bispecific antibody-cytokine fusion | Fibronectin extra domain B (EDB); IL-2 receptor; TNF receptor | Oncology |
Therapeutic area mix
- Oncology · 3
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AbbVie (prior sponsor, Abbott) · 1 shared drug class
- Abbott · 1 shared drug class
- Altuğ Güner · 1 shared drug class
- Alvotech Swiss AG · 1 shared drug class
- Asan Medical Center · 1 shared drug class
- Assistance Publique Hopitaux De Marseille · 1 shared drug class
- Bio-Thera Solutions · 1 shared drug class
- ASIS Corporation · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Philogen S.p.A.:
- Philogen S.p.A. pipeline updates — RSS
- Philogen S.p.A. pipeline updates — Atom
- Philogen S.p.A. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Philogen S.p.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/philogen-s-p-a. Accessed 2026-06-10.